Want to see MOLN full AI Analyst Report?
Molecular Partners (MOLN) Drug Pipeline
56 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 1, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 2-Arm A, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) + Azacitidine + Venetoclax, Mp0533 With Obinutuzumab Pretreatment, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B Relapsed/Refractory Aml, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B In Treatment Naïve Patients | Newly Diagnosed, Leukemia, Myeloid, Acute | phase1AndPhase2 | Recruiting | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | Dec 14, 2022 | ― |
| Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q3w Regimen), Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q1w Regimen) | Advanced Malignant Solid Tumor | Phase I | Terminated | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Sep 30, 2021 | ― |
| Ensovibep | Covid-19 | Phase I | Terminated | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) | Apr 28, 2021 | ― |
| Ensovibep | COVID19 | Phase II | Completed | Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients | Apr 06, 2021 | ― |
| Ensovibep | Covid-19 | phase2AndPhase3 | Terminated | A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 | Mar 24, 2021 | ― |
| Mp0310 | Advanced Solid Tumor | Phase I | Completed | Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors | Aug 05, 2019 | ― |
| Mp0250 Darpin® Drug Candidate, Osimertinib | Egfr-Mutated Nsclc (Disorder) | Phase I | Terminated | MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Jan 10, 2018 | ― |
| Mp0250 Plus Bor+Dex | Multiple Myeloma In Relapse | phase1AndPhase2 | Completed | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | Apr 18, 2017 | ― |
| Mp0274 | Neoplasms | Phase I | Completed | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors | Mar 06, 2017 | ― |
| Mp0250 | Neoplasms | phase1AndPhase2 | Completed | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients | Jun 12, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 1, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 2-Arm A, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) + Azacitidine + Venetoclax, Mp0533 With Obinutuzumab Pretreatment, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B Relapsed/Refractory Aml, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B In Treatment Naïve Patients | phase1AndPhase2 | Newly Diagnosed, Leukemia, Myeloid, Acute | Recruiting | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | Dec 14, 2022 | ― |
| Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q3w Regimen), Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q1w Regimen) | Phase I | Advanced Malignant Solid Tumor | Terminated | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Sep 30, 2021 | ― |
| Ensovibep | Phase I | Covid-19 | Terminated | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) | Apr 28, 2021 | ― |
| Ensovibep | Phase II | COVID19 | Completed | Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients | Apr 06, 2021 | ― |
| Ensovibep | phase2AndPhase3 | Covid-19 | Terminated | A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 | Mar 24, 2021 | ― |
| Mp0310 | Phase I | Advanced Solid Tumor | Completed | Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors | Aug 05, 2019 | ― |
| Mp0250 Darpin® Drug Candidate, Osimertinib | Phase I | Egfr-Mutated Nsclc (Disorder) | Terminated | MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Jan 10, 2018 | ― |
| Mp0250 Plus Bor+Dex | phase1AndPhase2 | Multiple Myeloma In Relapse | Completed | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | Apr 18, 2017 | ― |
| Mp0274 | Phase I | Neoplasms | Completed | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors | Mar 06, 2017 | ― |
| Mp0250 | phase1AndPhase2 | Neoplasms | Completed | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients | Jun 12, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Molecular Partners Ag (MOLN) have in its pipeline
Molecular Partners MOLN is currently developing the following drugs: Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 1, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) Monotherapy, Part 2-Arm A, Mp0533 (Multispecific Darpin Cd3 Engager Targeting Cd33, Cd123 And Cd70) + Azacitidine + Venetoclax, Mp0533 With Obinutuzumab Pretreatment, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B Relapsed/Refractory Aml, Mp0533 + Azacitidine + Venetoclax With Optional Obinutuzumab Pretreatment, Arm B In Treatment Naïve Patients, Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q3w Regimen), Mp0317, A Tri-Specific Fibroblast Activation Protein (Fap) X Cd40 Darpin® Drug Candidate (Q1w Regimen), Ensovibep, Mp0310, Mp0250 Darpin® Drug Candidate, Osimertinib, Mp0250 Plus Bor+Dex, Mp0274, Mp0250. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
